Israel - inglés - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 80 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.

Israel - inglés - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 40 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.

Israel - inglés - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 5 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.

Israel - inglés - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 5 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.

Israel - inglés - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - inhalation suspension for nebulisation - fluticasone propionate 0.5 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.children and adolescents from 4 to 16 years of age:treatment of acute exacerbations of asthma.

Israel - inglés - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - inhalation suspension for nebulisation - fluticasone propionate 2 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.

Israel - inglés - Ministry of Health

boehringer ingelheim israel ltd. - alteplase - powder and solvent for solution for injection/infusion - alteplase 50 mg/vial - enzymes - acute myocardial infarction :actilyse is indicated for use in the management of acute myocardial infraction (ami) in adults for the lysis of thrombi obstructing coronary arteries, the reduction of infract size, improvement of ventricular function, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with ami. treatment should be initiated as soon as possible after the onset of ami symptoms.acute massive pulmonary embolism with hemodynamic deprivation:actylise is indicated in the management of acute massive pulmonary embolism (pe) in adults:- for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lung, and- for the lysis of pulmonary emboli accompanied by unstable hemodynamics e.g. failure to maintain blood pressure without supportive measures. the diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning. for fibrinolytic treatment of acute ischaemic stroke.treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). the treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome. this treatment is restricted to a prescription by a specialist in neurology.

Israel - inglés - Ministry of Health

boehringer ingelheim israel ltd. - alteplase - powder and solvent for solution for injection/infusion - alteplase 20 mg/vial - enzymes - acute myocardial infarction :actilyse is indicated for use in the management of acute myocardial infraction (ami) in adults for the lysis of thrombi obstructing coronary arteries, the reduction of infract size, improvement of ventricular function, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with ami. treatment should be initiated as soon as possible after the onset of ami symptoms.acute massive pulmonary embolism with hemodynamic deprivation:actylise is indicated in the management of acute massive pulmonary embolism (pe) in adults:- for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lung, and- for the lysis of pulmonary emboli accompanied by unstable hemodynamics e.g. failure to maintain blood pressure without supportive measures. the diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning. for fibrinolytic treatment of acute ischaemic stroke.treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). the treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome. this treatment is restricted to a prescription by a specialist in neurology.

Singapur - inglés - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - abiraterone acetate - tablet - 250mg - abiraterone acetate 250mg

Australia - inglés - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - certolizumab pegol, quantity: 200 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; water for injections - rheumatoid arthritis cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients. ? combined with mtx in case of either an inadequate response or intolerance to previous therapy with one or more disease modifying antirheumatic drugs (dmards) or ? as monotherapy in case of a contraindication or intolerance to mtx (see section 4.2 dose and method of administration). cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray, when given in combination with mtx. cimzia in combination with mtx is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with mtx or other dmards.,psoriatic arthritis cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease modifying antirheumatic drug therapy (dmards) has been inadequate. cimzia has been shown to improve physical function.,ankylosing spondylitis cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug (nsaid).,non-radiographic axial spondyloarthritis cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axspa) with objective signs of inflammation as indicated by elevated c reactive protein (crp) and /or magnetic resonance imaging (mri) change, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs (nsaids).,plaque psoriasis cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.